A randomized controlled trial on home blood pressure monitoring and quality of care in stage 2 and 3 hypertension

Zhang, Di; Huang, Qi‐Fang; Li, Yan; Wang, Ji‐Guang

doi:10.1038/s41440-020-00602-0

Cited by 11 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Marquez-Contreras et al [ 56 ] reported that HBPM can improve drug adherence in patients with hypertension. Similarly, Zhang et al [ 57 ] also demonstrated HBPM improved treatment adherence and BP control despite similar antihypertensive treatment. Recently, the logic and the behavioral mechanism behind the influence of HBPM on adherence has begun to be investigated [ 58 ].…”

Section: Hbpm For Rht Managementmentioning

confidence: 85%

Role of home blood pressure monitoring in resistant hypertension

Kim

Shin

2023

Clin Hypertens

View full text Add to dashboard Cite

The definition of resistant hypertension (RHT) has been updated to include failure to achieve target blood pressure (BP) despite treatment with ≥3 antihypertensive drugs, including diuretics, renin-angiotensin system blockers, and calcium channel blockers, prescribed at the maximum or maximally tolerated doses, or as success in achieving the target blood pressure but requiring ≥4 drugs. RHT is a major clinical problem, as it is associated with higher mortality and morbidity than non-RHT. Therefore, it is crucial to accurately identify RHT patients to effectively manage their disease. Out-of-clinic BP measurement, including home BP monitoring and ambulatory BP monitoring is gaining prominence for the diagnosis and management of RHT. Home BP monitoring is advantageous as it is feasibly repetitive, inexpensive, widely available, and because of its reproducibility over long periods. In addition, home BP monitoring has crucial advantage of allowing safe titration for the maximum or maximally tolerable dose, and for self-monitoring, thereby improving clinical inertia and nonadherence, and allowing true RHT to be more accurately identified.

show abstract

Section: Hbpm For Rht Managementmentioning

confidence: 85%

Role of home blood pressure monitoring in resistant hypertension

Kim

Shin

2023

Clin Hypertens

View full text Add to dashboard Cite

show abstract

“…5 ). Zhan et al [ 83 ] demonstrated that HBP monitoring improved treatment adherence and BP control in stage 2 and 3 hypertension. Hoshide et al [ 84 ] demonstrated the association of nighttime BP assessed by HBP and CVD events, independent of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, in the Japanese clinical population.…”

Section: Appropriate Blood Pressure Assessment Methods For the Preven...mentioning

confidence: 99%

Update on Hypertension Research in 2021

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The study participants were patients enrolled in a 12-week therapeutic study in stage 2 and 3 hypertension. The protocol of the study had been described in detail previously [19,20]. Briefly, men and women (18–75 years) with an SBP/DBP of 160–199/100–119 mm Hg after a 1-week wash-out run-in phase started antihypertensive treatment with the single-pill combination of irbesartan 150 mg and hydrochlorothiazide 12.5 mg once daily.…”

Section: Methodsmentioning

confidence: 99%

“…We recently found in an antihypertensive drug trial that there was a substantial variation in serum uric acid that was associated with the use of the irbesartan/hydrochlorothiazide combination therapy [19,20]. In the present analysis, we investigated serum uric acid change and incident hyperuricemia in relation to the achieved BP during antihypertensive therapy with the irbesartan/hydrochlorothiazide combination.…”

Section: Introductionmentioning

confidence: 99%

Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination

Zhang

Huang²,

Li³

et al. 2021

Blood Pressure Monitoring

Self Cite

View full text Add to dashboard Cite

Objective We investigated serum uric acid changes and incident hyperuricemia in relation to the achieved blood pressure (BP) after 12 weeks of antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. Methods The study participants were 449 patients who completed the study. Analysis of covariance and multiple logistic regression analyses were performed to calculate the least square mean changes (± standard error) from baseline in serum uric acid and odds ratios (ORs) for incident hyperuricemia according to the achieved levels of BP. Results Adjusted analyses showed that serum uric acid changes differed according to the achieved SBP/DBP (P = 0.002), with a smaller mean (± standard error) increase in the range of 130–139/<90 mm Hg (n = 132, 19.8 ± 5.7 µmol/L) than that of ≥140/90 (n = 129, 32.4 ± 7.3 µmol/L) or <130/90 mm Hg (n = 188, 39.5 ± 5.1 µmol/L). Adjusted analyses showed similar results for the incident hyperuricemia (n = 95, 24.0%) in those patients with normal serum uric acid at baseline (n = 396). The risk of incident hyperuricemia was lower (OR, 0.45; 95% confidence interval 0.25–0.83; P = 0.04) in patients with an achieved SBP/DBP of 130–139/<90 mm Hg (n = 117, incidence rate, 17.1%) than those with an achieved SBP/DBP of ≥140/90 (n = 118, 31.4%) or <130/90 mm Hg (n = 161, 23.6%). Conclusions Thiazide-induced changes in serum uric acid or incident hyperuricemia were associated with the achieved SBP/DBP, being lower at the level of 130–139/<90 mm Hg.

show abstract

A randomized controlled trial on home blood pressure monitoring and quality of care in stage 2 and 3 hypertension

Cited by 11 publications

References 29 publications

Role of home blood pressure monitoring in resistant hypertension

Role of home blood pressure monitoring in resistant hypertension

Update on Hypertension Research in 2021

Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination

Contact Info

Product

Resources

About